UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
CURRENT REPORT
February 18, 2005
Date of Report (date of Earliest Event Reported)
ISOLAGEN, INC.
(Exact Name of Registrant as Specified in its Charter)
|
DELAWARE |
|
001-31564 |
|
87-0458888 |
|
(State or Other Jurisdiction of |
|
(Commission File No.) |
|
(I.R.S. Employer Identification No.) |
2500 Wilcrest, 5th Floor, Houston, Texas 77042
(Address of principal executive offices and zip code)
(713) 780-4754
(Registrant’s telephone number, including area code)
(Former name or former address, if changed from last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).
Item 7.01 Regulation FD Disclosure
Isolagen announces that the twelve-month follow-up data from a Phase III Exploratory Clinical Trial indicates sustained positive effects in patients who received the Isolagen Process. See Exhibit 99.1, which is specifically incorporated by reference herein, for further information.
Item 9.01 Financial Statements and Exhibits
(a) Not applicable.
(b) Not applicable.
(c) Exhibits.
99.1 Press release dated February 18, 2005
2
SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
ISOLAGEN, INC. |
||
|
|
|
||
|
|
|
||
|
Date: February 18, 2005 |
By: |
/s/ Jeffrey Tomz |
|
|
|
|
Chief Financial Officer |
|
3